Victoria Socha

DocwireNews

Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis. Central in the pathogenesis of IgAN are galactose-deficient IgA1 (GD-IgA1), anti-GD-IgA1 autoantibodies (anti-Gd-IgA1), and IgA-IgA-containing immune complexes (ICs), all contributing to kidney damage. The phase 2a JANUS trial (NCT02808429) evaluating the safety and efficacy of atacicept in patients with IgAN demonstrated the potential of targeting the disease-causing species.During a late-breaking session at the ERA 60th Congress, Richard Lafayette, MD, and colleagues presented preliminary results of the phase 2b ORIGIN trial (NCT04716231) in a presentation titled ORIGIN Trial: 24-wk Primary Analysis of a Randomized, Double-Blind, Placebo-Controlled PH2B Study of Atacicept in Patients With IgAN. Atacicept is a fusion protein that binds B-lymphocyte stimulator and a proliferation inducing ligand to inhibit maturation and class-switching of B-cells and plasma cells.The ORIGIN cohort includes 116 patients with biopsy-proven IgAN, 24-hour urine protein &gt;0.75 g per day or urine protein-to-creatinine ratio (UPCR) &gt;0.75 g/g, and estimated glomerular filtration rate (eGFR) &gt;30 mL/min/1.73 m2 despite treatment with optimized renin-angiotensin system blockade. Patients were randomized to atacicept 150 mg, 75 mg, or 25 mg administered via subcutaneous injection once per week versus placebo (2:2:1:2) for up to 36 weeks. The primary end point was the change in 24-hour UPCR at 24 weeks in the pooled atacicept 150 mg and 75 mg arms compared with placebo.Of the 116 patients in the intent-to-treat (ITT) population, 33, 33, and 16 received atacicept 150, 75, and 25 mg, respectively, and 34 received placebo. In the pooled 75 and 150 mg atacicept arms, mean UPCR at 24 weeks was reduced from baseline by 31% compared with a 7% reduction from baseline in the placebo arm. Results of the ITT analysis are supported by a prespecified per-protocol analysis: the atacicept 150 mg arm showed a 41% reduction from baseline in UPCR at 24 weeks compared with a 10% reduction in the placebo arm.For the secondary outcome, eGFR showed stability at week 24 in the atacicept 150 mg arm. Safety results demonstrated that atacicept was generally well tolerated, with no increased rates of infection compared with placebo and a low rate (2%) of serious adverse events overall, with no serious adverse events in the atacicept 150 mg arm.&ldquo;The ORIGIN Ph2b study met its primary end point, demonstrating a favorable impact on disease biomarkers and a clinically meaningful reduction in proteinuria and demonstrated a favorable safety profile,&rdquo; the researchers said. &ldquo;These promising results at Week 24 support atacicept 150 mg for further evaluation as a potential disease modifying treatment of patients with IgA nephropathy.&rdquo;Source: Lafayette R, Maes B, Lin C, et al. ORIGIN trial:24-wk primary analysis of a randomized, double-blind, placebo-controlled ph2b study of atacicept in patients with IgAN. Presentation #3848. Abstract of a presentation at the European Renal Association 60th Congress; June 15-18, 2023; Milan, Italy. ORIGIN is supported by Vera Therapeutics, Inc.&nbsp;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

ORIGIN: 24-Week Results of Phase 2b Trial of Atacicept in Patients With IgAN

IgA Nephropathy

In the pooled 75 and 150 mg atacicept arms, mean UPCR at 24 weeks was reduced from baseline by 31% compared with a 7% reduction from baseline in the placebo arm. 

ORIGIN: 24-Week Results of Phase 2b Trial of Atacicept in Patients with IgAN

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe